Non-alcoholic steatohepatitis (NASH) is a type of NAFLD (nonalcoholic fatty liver disease), which is the condition with stored excess of fat in liver. NAFLD is characterized by steatosis of the liver, and NASH is a necro-inflammatory process whereby the liver cells become injured  under steatosis.

Prevalence rate of NAFLD in China is estimated at 15.0%, or 208.5 million NAFLD patients, in 2017, and is expected to increase as less exercise and other lifestyle changes in the PRC population increase the risk of obesity.

Although there is a huge patient pool and unmet medical needs, currently there are no approved NASH drugs in the world. We are develop in-house breakthrough therapies for NASH focusing on novel targets.